SNY News and Press, Sanofi From 06/25/24

2024-06-25 11:08:09 ET Eli Lilly and Company ( NYSE: LLY ) said on Tuesday that it is collaborating with Microsoft ( MSFT ) backed-OpenAI that will help leverage generative AI to invent novel antimicrobials to treat drug-resistant pathogens.... Read the full article on See...

2024-06-24 13:25:16 ET More on Sanofi Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Sanofi Q1: Wait And See For Now (Downgrade) Innate falls on updated phase 1/2 data on blood cancer asset...

2024-06-20 15:02:43 ET Summary Novavax, Inc. secured a lucrative deal with Sanofi, receiving potentially $1.2 billion in cash and future royalties for Covid vaccines. The deal significantly improved Novavax's financial position, but the stock has already rallied from $4 to $14, li...

2024-06-20 06:53:11 ET Summary Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well...

2024-06-18 10:05:23 ET Summary Apogee Therapeutics stock has declined by 34% since a previous recommendation to buy, while the S&P 500 is up 7.7%. Apogee Therapeutics raised $420 million at $62/share, expanding their financial runway while advancing APG777 into Phase 2 trials....

2024-06-17 12:55:20 ET More on Sanofi, Innate Pharma Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Innate Pharma: Worth A Deeper Look Regeneron, Sanofi win FDA label expansion for ar...

2024-06-16 07:19:35 ET Summary Sanofi's shares have not fully recovered since announcing a business strategy change in October 2023, focusing on R&D investments and on separating its consumer healthcare business unit. The company's immunology business, led by Dupixent and othe...

2024-06-14 14:38:51 ET Summary Avidity Biosciences, Inc.'s FORTITUDE trial of AOC 1020 in treating FSHD showed promising reductions in DUX4 gene expression and improvements in muscle function. The trial reported favorable safety and tolerability, with no serious adverse events or ...

2024-06-14 10:59:33 ET More on bird flu CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Virax surges amid bird flu concerns Bird flu death in Mexico linked to strain not seen in humans before Third human bird flu case found...

2024-06-14 05:06:33 ET Summary In recent weeks, Sanofi has pleased investors with progress in the development of its pipeline of experimental drugs. On May 20, 2024, SNY announced additional results from a Phase 3 clinical trial that demonstrated Dupixent's greater efficacy in COP...